search
Back to results

Renal Denervation in Patients With Refractory Hypertension (HTN-1)

Primary Purpose

Hypertension

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Symplicty(TM) Catheter System
Sponsored by
Medtronic Vascular
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • >= 18 years of age
  • a systolic blood pressure of 160mmHg or more
  • receiving and adhering to full doses of at least three antihypertensive drugs
  • estimated glomerular filtration rate (eGFR) of ≥45mL/min
  • agrees to have the study procedure(s) performed and additional procedures and evaluations
  • is competent and willing to provide written, informed consent to participate in this clinical study

Exclusion Criteria:

  • hemodynamically or anatomically significant renal artery stenosis
  • has a history or prior renal artery angioplasty
  • has experienced MI, unstable angina pectoris, or CVA within 6 months
  • has hemodynamically significant valvular heart disease
  • has Type 1 diabetes
  • has an implantable cardioverter defibrillator (ICD) or pacemaker, or any other metallic implant which is not compatible with magnetic resonance imaging (MRI)
  • requires respiratory support
  • is pregnant, nursing, or planning to be pregnant
  • has known, unresolved history of drug use or alcohol dependency.
  • is currently enrolled in another investigational drug or device trial.

Sites / Locations

  • Herzzentrum Bad Krozingen
  • St. Elisabeth Hospital
  • Klinikum Coburg
  • Universitaetsklinikum Duesseldorf
  • University of Erlangen at Nuremburg
  • CardioVascular Center Frankfurt, Sankt Katharinen
  • Clinical Trial Center North
  • Universitatskliniken des Saarlandes
  • University of Leipzig - Herzzentrum

Outcomes

Primary Outcome Measures

To document that renal denervation achieved via the delivery of RF energy is safe, and not associated with clinically significant adverse events, in patients with refractory hypertension.

Secondary Outcome Measures

To document the physiologic effects of renal denervation in patients with refractory hypertension.

Full Information

First Posted
April 21, 2008
Last Updated
November 1, 2013
Sponsor
Medtronic Vascular
search

1. Study Identification

Unique Protocol Identification Number
NCT00664638
Brief Title
Renal Denervation in Patients With Refractory Hypertension
Acronym
HTN-1
Official Title
Renal Denervation in Patients With Refractory Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
May 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Vascular

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To investigate the clinical utility of renal denervation in the treatment of refractory hypertension.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
45 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Symplicty(TM) Catheter System
Intervention Description
Renal denervation using the Symplicity Catheter System
Primary Outcome Measure Information:
Title
To document that renal denervation achieved via the delivery of RF energy is safe, and not associated with clinically significant adverse events, in patients with refractory hypertension.
Time Frame
3 years
Secondary Outcome Measure Information:
Title
To document the physiologic effects of renal denervation in patients with refractory hypertension.
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: >= 18 years of age a systolic blood pressure of 160mmHg or more receiving and adhering to full doses of at least three antihypertensive drugs estimated glomerular filtration rate (eGFR) of ≥45mL/min agrees to have the study procedure(s) performed and additional procedures and evaluations is competent and willing to provide written, informed consent to participate in this clinical study Exclusion Criteria: hemodynamically or anatomically significant renal artery stenosis has a history or prior renal artery angioplasty has experienced MI, unstable angina pectoris, or CVA within 6 months has hemodynamically significant valvular heart disease has Type 1 diabetes has an implantable cardioverter defibrillator (ICD) or pacemaker, or any other metallic implant which is not compatible with magnetic resonance imaging (MRI) requires respiratory support is pregnant, nursing, or planning to be pregnant has known, unresolved history of drug use or alcohol dependency. is currently enrolled in another investigational drug or device trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Henry Krum, PhD
Organizational Affiliation
Monash University and The Alfred Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Herzzentrum Bad Krozingen
City
Bad Krozingen
Country
Germany
Facility Name
St. Elisabeth Hospital
City
Bochum
Country
Germany
Facility Name
Klinikum Coburg
City
Coburg
Country
Germany
Facility Name
Universitaetsklinikum Duesseldorf
City
Duesseldorf
Country
Germany
Facility Name
University of Erlangen at Nuremburg
City
Erlangen
Country
Germany
Facility Name
CardioVascular Center Frankfurt, Sankt Katharinen
City
Frankfurt
Country
Germany
Facility Name
Clinical Trial Center North
City
Hamburg
Country
Germany
Facility Name
Universitatskliniken des Saarlandes
City
Homburg
Country
Germany
Facility Name
University of Leipzig - Herzzentrum
City
Leipzig
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
24210779
Citation
Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014 Feb 15;383(9917):622-9. doi: 10.1016/S0140-6736(13)62192-3. Epub 2013 Nov 7. Erratum In: Lancet. 2014 Feb 15;383(9917):602. Sobotka, Paul A [added].
Results Reference
derived
PubMed Identifier
23780578
Citation
Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Bohm M. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013 Jul 9;128(2):132-40. doi: 10.1161/CIRCULATIONAHA.112.000949. Epub 2013 Jun 18. Erratum In: Circulation. 2014 May 20;129(20):e502.
Results Reference
derived
PubMed Identifier
21518978
Citation
Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Bohm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011 May 10;123(18):1940-6. doi: 10.1161/CIRCULATIONAHA.110.991869. Epub 2011 Apr 25.
Results Reference
derived
PubMed Identifier
19332353
Citation
Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009 Apr 11;373(9671):1275-81. doi: 10.1016/S0140-6736(09)60566-3. Epub 2009 Mar 28.
Results Reference
derived

Learn more about this trial

Renal Denervation in Patients With Refractory Hypertension

We'll reach out to this number within 24 hrs